- In a P-I study, patients were treated initially for 14wks. with UV1 + pembrolizumab and patient in the first cohort had been followed for at least 24mos. from the start of their treatment, @ cut-off date of Oct 12, 2021
- After @2yrs. follow up, OS (80%) in the first cohort of 20 patients. mPFS (18.9mos.). The 24mos. follow-up data compares favorably with an earlier large-scale study of pembrolizumab alone that demonstrated an OS rate of 58% after 24mos. and mPFS of 5.5-11.6mos.
- The 2yrs. follow-up data suggested that the way in which UV1 mobilizes the immune system provides long benefits to the patients
Click here to read full press release/ article | Ref: Globe Newswire | Image: Businesswire